#Denmark #Copenhagen #Hedia #Rasmus Kofoed #Lars Christian Lund

Hedia Announces New CEO: Rasmus Kofoed

Hedia, a leading Danish company specializing in diabetes technology, is preparing for a significant leadership transition. Effective December 1, 2025, Rasmus Kofoed will take over as Chief Executive Officer from Lars Christian Lund, who has decided to resign after nearly two years in the position to assume a CEO role at another international company.

This change in leadership is seen as a pivotal moment for Hedia, which has positioned itself as a European leader in digital diabetes management since its inception in 2016. Under Lars Christian Lund’s guidance, Hedia has evolved from an ambitious startup to a professionally expanded enterprise, completing solid regulatory and commercial developments.

The Chairman of the Board, Carl Bilbo, expressed gratitude for Lund's contributions, noting his crucial role in strengthening the organization, achieving Medical Device Regulation (MDR) approvals, and laying the groundwork for global growth. Bilbo stated, "We thank Lars for his outstanding contributions and welcome Rasmus as our new CEO. Rasmus's strategic and commercial acumen in life sciences and medical technology makes him the perfect fit to lead Hedia into its next phase."

Rasmus Kofoed comes with an impressive track record in the life sciences and medical technology sectors. Previously, he held key executive roles at renowned companies, including Novo Nordisk, Abbott, Roche, and Medtronic. He served as CEO of ChemoMetec, managing overall commercial and strategic responsibilities, including growth, transformation, and international expansion.

On his appointment, Rasmus Kofoed stated, "I see enormous potential in Hedia. The company uniquely blends clinical knowledge with technology to create real value for people living with diabetes. I eagerly look forward to collaborating with the team to broaden our reach, enhance our partnerships, and continue our mission to position Hedia as a leader in digital diabetes care."

With this leadership transition, Hedia is set to mark a natural progression in its growth journey while reaffirming its commitment to expanding its international presence and commercial endeavors. The company continues to focus on developing innovative digital solutions that empower insulin-dependent individuals to better understand and manage their treatment using data, artificial intelligence, and user-friendly application technologies.

For more information about Hedia and its initiatives, please visit www.hedia.com.